Iantrek

Iantrek, Inc. is an ophthalmic medical technology company founded in 2019 by Dr. Sean Ianchulev, a prominent innovator in the field. Based in White Plains, New York, with research and development offices in Providence, Rhode Island, Iantrek focuses on creating advanced surgical technologies to improve the treatment of chronic eye diseases, particularly glaucoma. The company offers several key products, including the CycloPen™ System, which targets the suprachoroidal outflow pathway to reduce intraocular pressure, and the AlloFlo™ Bio-Tissue Implant, designed to enhance uveoscleral outflow. Additionally, the C-Rex™ Device facilitates traditional goniotomy surgery for improved aqueous humor outflow. Iantrek's technologies are the only FDA-cleared solutions aimed at enhancing the uveoscleral outflow pathway, demonstrating clinical success in long-term efficacy and safety for glaucoma patients. Iantrek serves ophthalmic surgeons and specialized eye care centers, with plans for broader commercialization of its products in the U.S. market by the third quarter of 2025. The company is committed to leading innovation in biointerventional ophthalmic surgery through its minimally invasive solutions.

• Employees 54
• Founded 2019
• Annual Revenue $1500000
• Total Funding $65000000